A Two-part, Single- and Two Arm Randomized, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy (in Part 2 Only) of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies

Trial Profile

A Two-part, Single- and Two Arm Randomized, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy (in Part 2 Only) of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Mar 2018

At a glance

  • Drugs Mocravimod (Primary)
  • Indications Transplant rejection
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 22 Mar 2018 Planned End Date changed from 25 Jan 2020 to 24 Aug 2018.
    • 22 Mar 2018 Planned primary completion date changed from 25 Jan 2020 to 24 Aug 2018.
    • 22 Mar 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top